Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 21
Filtrar
Más filtros

Medicinas Complementárias
Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Cell Host Microbe ; 22(4): 531-542.e8, 2017 Oct 11.
Artículo en Inglés | MEDLINE | ID: mdl-28943329

RESUMEN

Diet, and specifically dietary metals, can modify the risk of infection. However, the mechanisms by which manganese (Mn), a common dietary supplement, alters infection remain unexplored. We report that dietary Mn levels dictate the outcome of systemic infections caused by Staphylococcus aureus, a leading cause of bacterial endocarditis. Mice fed a high Mn diet display alterations in Mn levels and localization within infected tissues, and S. aureus virulence and infection of the heart are enhanced. Although the canonical mammalian Mn-sequestering protein calprotectin surrounds staphylococcal heart abscesses, calprotectin is not released into the abscess nidus and does not limit Mn in this organ. Consequently, excess Mn is bioavailable to S. aureus in the heart. Bioavailable Mn is utilized by S. aureus to detoxify reactive oxygen species and protect against neutrophil killing, enhancing fitness within the heart. Therefore, a single dietary modification overwhelms vital host antimicrobial strategies, leading to fatal staphylococcal infection.


Asunto(s)
Endocarditis Bacteriana/microbiología , Corazón/microbiología , Manganeso/metabolismo , Infecciones Estafilocócicas/microbiología , Staphylococcus aureus/metabolismo , Absceso , Animales , Dieta , Modelos Animales de Enfermedad , Corazón/fisiopatología , Humanos , Complejo de Antígeno L1 de Leucocito/metabolismo , Hígado/microbiología , Hígado/fisiopatología , Manganeso/análisis , Ratones , Ratones Congénicos , Ratones Endogámicos C57BL , Neutrófilos/metabolismo , Especies Reactivas de Oxígeno/metabolismo , Staphylococcus aureus/patogenicidad
2.
Antimicrob Agents Chemother ; 56(8): 4439-49, 2012 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-22687510

RESUMEN

We have shown previously that high-dose lipid amphotericin preparations are not more efficacious than lower doses in aspergillosis. We studied toxicity, drug concentrations and localization, and quantitative infection concurrently, using a 4-day model of central nervous system (CNS) aspergillosis to assess early events. Mice given Aspergillus fumigatus conidia intracerebrally, under a cyclophosphamide immunosuppressive regimen, were treated for 3 days (AmBisome at 3 or 10 mg/kg of body weight, Abelcet at 10 mg/kg, amphotericin B deoxycholate at 1 mg/kg, caspofungin at 5 mg/kg, or voriconazole at 40 mg/kg). Sampling 24 h after the last treatment showed that AmBisome at 3 but not at 10 mg/kg, as well as Abelcet, caspofungin, and voriconazole, reduced brain CFU. All regimens reduced renal infection. Minor renal tubular changes occurred with AmBisome or Abelcet therapy, whereas heart, lung, and brain showed no drug toxicity. Amphotericin B tissue and serum concentrations did not correlate with efficacy. Endothelial cell activation (ICAM-1 and P-selectin in cerebral capillaries) occurred during infection. Amphotericin B derived from AmBisome and Abelcet localized in activated endothelium and from Abelcet in intravascular monocytes. In 10-day studies dosing uninfected mice, minor renal tubular changes occurred after AmBisome or Abelcet at 1, 5, or 10 mg/kg with or without cyclophosphamide treatment; nephrosis occurred only with Abelcet in cyclophosphamide-treated mice. Hepatotoxicity occurred with AmBisome and Abelcet but was reduced in cyclophosphamide-treated mice. Marked CFU reduction by AmBisome at 3 mg/kg occurred in association with relatively more intense inflammation. Abelcet renal localization appears to be a precursor to late nephrotoxicity. Hepatotoxicity may contribute to high-dose Abelcet and AmBisome failures. Our novel observation of endothelial amphotericin localization during infection may contribute to amphotericin mechanism of efficacy.


Asunto(s)
Anfotericina B/uso terapéutico , Antifúngicos/uso terapéutico , Aspergillus fumigatus/efectos de los fármacos , Ácido Desoxicólico/uso terapéutico , Neuroaspergilosis/tratamiento farmacológico , Anfotericina B/sangre , Anfotericina B/farmacología , Animales , Antifúngicos/farmacología , Aspergillus fumigatus/patogenicidad , Encéfalo/efectos de los fármacos , Encéfalo/microbiología , Caspofungina , Ciclofosfamida , Ácido Desoxicólico/sangre , Ácido Desoxicólico/farmacología , Combinación de Medicamentos , Equinocandinas/farmacología , Equinocandinas/uso terapéutico , Células Endoteliales/efectos de los fármacos , Corazón/efectos de los fármacos , Corazón/microbiología , Terapia de Inmunosupresión , Molécula 1 de Adhesión Intercelular/biosíntesis , Riñón/efectos de los fármacos , Riñón/microbiología , Lipopéptidos , Pulmón/efectos de los fármacos , Pulmón/microbiología , Masculino , Ratones , Nefrosis , Neuroaspergilosis/sangre , Neuroaspergilosis/microbiología , Selectina-P/biosíntesis , Pirimidinas/farmacología , Pirimidinas/uso terapéutico , Triazoles/farmacología , Triazoles/uso terapéutico , Voriconazol
3.
Med Parazitol (Mosk) ; (4): 40-2, 2012.
Artículo en Ruso | MEDLINE | ID: mdl-23437723

RESUMEN

Experiments have established that the first target for echinococcus is the liver and lung and that for pathogenic fungi and protozoa is the heart. Adult patients with hepatic hydatid disease complicated by paecilomycosis have been found to have atypical paecilomycosis-associated myocarditis, the treatment of which was developed by the authors, by using antibiotics, fungicides, and homeopathic remedies.


Asunto(s)
Equinococosis/complicaciones , Corazón/fisiopatología , Micosis/complicaciones , Miocarditis/complicaciones , Sarcocistosis/complicaciones , Adulto , Anciano , Animales , Antibacterianos/uso terapéutico , Antifúngicos/uso terapéutico , Coinfección , Equinococosis/tratamiento farmacológico , Equinococosis/parasitología , Echinococcus/efectos de los fármacos , Echinococcus/fisiología , Femenino , Corazón/efectos de los fármacos , Corazón/microbiología , Corazón/parasitología , Humanos , Hígado/efectos de los fármacos , Hígado/microbiología , Hígado/parasitología , Pulmón/efectos de los fármacos , Pulmón/microbiología , Pulmón/fisiopatología , Masculino , Materia Medica/uso terapéutico , Persona de Mediana Edad , Micosis/tratamiento farmacológico , Micosis/microbiología , Miocarditis/tratamiento farmacológico , Miocarditis/microbiología , Miocarditis/parasitología , Paecilomyces/efectos de los fármacos , Paecilomyces/fisiología , Sarcocystis/efectos de los fármacos , Sarcocystis/fisiología , Sarcocistosis/tratamiento farmacológico , Sarcocistosis/parasitología
4.
Eur J Clin Microbiol Infect Dis ; 29(2): 239-43, 2010 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-20012879

RESUMEN

The cardiovascular drug lacidipine (Lc) is known to possess antibacterial activity. Further potentiation of action is possible by synergism between Lc and an antibiotic or a non-antibiotic. The minimum inhibitory concentration (MIC) of antibiotics, Lc and other non-antibiotics were detected by the agar dilution technique in different bacteria. Synergism was determined by disc diffusion assay, the fractional inhibitory concentration (FIC) index through checkerboard assessment and, also, the protective capacity of the combination by administering the drugs along with 50 x LD(50) challenge dose of virulent Salmonella typhimurium in animal experiments. Synergism between Lc and penicillin was found to be statistically significant (P

Asunto(s)
Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Dihidropiridinas/farmacología , Dihidropiridinas/uso terapéutico , Animales , Recuento de Colonia Microbiana , Modelos Animales de Enfermedad , Sinergismo Farmacológico , Bacterias Gramnegativas/efectos de los fármacos , Bacterias Grampositivas/efectos de los fármacos , Corazón/microbiología , Humanos , Hígado/microbiología , Masculino , Ratones , Pruebas de Sensibilidad Microbiana , Salmonelosis Animal/tratamiento farmacológico , Bazo/microbiología , Resultado del Tratamiento
5.
Medicine (Baltimore) ; 85(2): 86-94, 2006 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-16609347

RESUMEN

Endocarditis is uncommon in patients with cancer. The characteristics of culture-positive (CPE) and culture-negative endocarditis (CNE) in high-risk cancer patients are not known; therefore we sought to evaluate the disease characteristics in patients with endocarditis at a comprehensive cancer center. We retrospectively reviewed the transthoracic (TTE) and transesophageal (TEE) echocardiograms obtained from 654 consecutive cancer patients in whom endocarditis was suspected between 1994 and 2004. Endocarditis was confirmed in 45 (7%) of 654 patients using modified Duke University criteria based on information obtained from hospital records and computerized data systems. In 21 (95%) of 22 cases, TEE examinations were diagnostic, and 16 (42%) of 38 patients with initially nondiagnostic TTE studies had the diagnosis confirmed by TEE study; this difference between diagnostic TEE and initial nondiagnostic TTE was significant (p < 0.0001). Among the 26 (58%) patients with CPE, Staphylococcus aureus (35%) was the most common organism isolated, followed by coagulase-negative Staphylococcus species (23%). Eighteen (78%) of 23 patients with a central venous catheter had CPE, whereas only 8 (36%) of 22 patients without a central venous catheter had CPE (odds ratio [OR], 6.3; 95% confidence interval [CI], 1.69-23.53; p < 0.006). Vegetations were larger in patients with CPE than in patients with CNE (median +/- standard deviation, 10 +/- 8.8 vs. 8.7 +/- 3.9 mm). Fifteen patients (58%) with CPE and 10 (53%) with CNE had embolic complications. We note that cutaneous and septic pulmonary emboli were more common in patients with CPE than in patients with CNE (31% vs. 11% and 15% vs. 0%, respectively), whereas embolic cerebrovascular and fatal embolic coronary events were more common in patients with CNE than in those with CPE (37% vs. 12% and 21% vs. 0%, respectively; p = 0.026). The 4-week endocarditis-attributable death rate did not differ significantly between the groups (CPE, 15% vs. CNE, 32%; p = 0.28). On stepwise multivariate regression analysis, patients with neutropenia (OR, 22.52; 95% CI, 2.25-225.48; p < 0.008) and those with embolic cerebrovascular events (OR, 17.07; 95% CI, 1.63-178.45; p < 0.01) had an increased probability of death due to endocarditis. The clinical spectrums of CPE and CNE differed in these patients with cancer. In patients with CNE, embolic cerebrovascular and fatal myocardial infarction were relatively common.


Asunto(s)
Endocarditis Bacteriana/complicaciones , Endocarditis/complicaciones , Infecciones por Bacterias Gramnegativas/complicaciones , Infecciones por Bacterias Grampositivas/complicaciones , Neoplasias/complicaciones , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Ecocardiografía , Ecocardiografía Transesofágica , Endocarditis/diagnóstico , Endocarditis Bacteriana/diagnóstico , Endocarditis Bacteriana/mortalidad , Endocarditis Bacteriana/patología , Femenino , Infecciones por Bacterias Gramnegativas/diagnóstico , Infecciones por Bacterias Gramnegativas/patología , Infecciones por Bacterias Grampositivas/diagnóstico , Infecciones por Bacterias Grampositivas/patología , Corazón/microbiología , Humanos , Embolia Intracraneal/diagnóstico , Embolia Intracraneal/etiología , Embolia Intracraneal/patología , Masculino , Persona de Mediana Edad , Análisis Multivariante , Infarto del Miocardio/diagnóstico , Infarto del Miocardio/etiología , Infarto del Miocardio/patología , Neoplasias/microbiología , Neoplasias/terapia , Embolia Pulmonar/diagnóstico , Embolia Pulmonar/etiología , Embolia Pulmonar/patología , Estudios Retrospectivos , Factores de Riesgo , Infecciones Estafilocócicas/complicaciones , Infecciones Estafilocócicas/diagnóstico , Infecciones Estafilocócicas/patología , Staphylococcus aureus/aislamiento & purificación , Tromboembolia/diagnóstico , Tromboembolia/etiología , Tromboembolia/patología
6.
Indian J Exp Biol ; 43(6): 566-8, 2005 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-15991585

RESUMEN

Based on its traditional uses in folk medicine, the whole flower extract of Mesua ferrea Linn. was tested for its in vitro antimicrobial efficacy against five different strains of Salmonella spp. All the strains were found to be highly sensitive to the extract, MIC of the extract against each organism being 50 microg/ml. The extract was tested in vitro for its mode of antibacterial activity against S. Typhimurium NCTC 74 and it was found to be bactericidal in action. In vivo studies of this extract offered significant protection to Swiss albino mice at doses approximately 2 and 4 mg/mouse when challenged with 50 median lethal dose of S. Typhimurium NCTC 74. Further, the extract caused statistically significant reduction in viable count of the strain in liver, spleen and heart blood of challenged mice.


Asunto(s)
Clusiaceae/metabolismo , Estructuras de las Plantas/metabolismo , Salmonelosis Animal/tratamiento farmacológico , Infecciones por Salmonella/tratamiento farmacológico , Salmonella typhimurium/metabolismo , Animales , Antiinfecciosos , Relación Dosis-Respuesta a Droga , Corazón/microbiología , Técnicas In Vitro , Hígado/microbiología , Ratones , Extractos Vegetales , Bazo/microbiología , Células Madre , Virulencia
7.
Antimicrob Agents Chemother ; 49(1): 380-7, 2005 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-15616318

RESUMEN

Therapeutic options for invasive Staphylococcus aureus infections have become limited due to rising antimicrobial resistance, making relevant animal model testing of new candidate agents more crucial than ever. In the present studies, a rat model of aortic infective endocarditis (IE) caused by a bioluminescently engineered, biofilm-positive S. aureus strain was used to evaluate real-time antibiotic efficacy directly. This strain was vancomycin and cefazolin susceptible but gentamicin resistant. Bioluminescence was detected and quantified daily in antibiotic-treated and control animals with IE, using a highly sensitive in vivo imaging system (IVIS). Persistent and increasing cardiac bioluminescent signals (BLS) were observed in untreated animals. Three days of vancomycin therapy caused significant reductions in both cardiac BLS (>10-fold versus control) and S. aureus densities in cardiac vegetations (P < 0.005 versus control). However, 3 days after discontinuation of vancomycin therapy, a greater than threefold increase in cardiac BLS was observed, indicating relapsing IE (which was confirmed by quantitative culture). Cefazolin resulted in modest decreases in cardiac BLS and bacterial densities. These microbiologic and cardiac BLS differences during therapy correlated with a longer time-above-MIC for vancomycin (>12 h) than for cefazolin ( approximately 4 h). Gentamicin caused neither a reduction in cardiac S. aureus densities nor a reduction in BLS. There were significant correlations between cardiac BLS and S. aureus densities in vegetations in all treatment groups. These data suggest that bioluminescent imaging provides a substantial advance in the real-time monitoring of the efficacy of therapy of invasive S. aureus infections in live animals.


Asunto(s)
Antibacterianos/uso terapéutico , Endocarditis Bacteriana/tratamiento farmacológico , Procesamiento de Imagen Asistido por Computador , Mediciones Luminiscentes , Staphylococcus aureus/efectos de los fármacos , Animales , Antibacterianos/farmacología , Endocarditis Bacteriana/microbiología , Endocarditis Bacteriana/fisiopatología , Femenino , Corazón/microbiología , Humanos , Pruebas de Sensibilidad Microbiana , Ratas , Ratas Sprague-Dawley , Infecciones Estafilocócicas/microbiología , Infecciones Estafilocócicas/fisiopatología , Resultado del Tratamiento
8.
Antimicrob Agents Chemother ; 48(8): 3051-6, 2004 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-15273120

RESUMEN

Platelet microbicidal proteins (PMPs) are believed to be integral to host defense against endovascular infection. We previously demonstrated that susceptibility to thrombin-induced PMP 1 (tPMP-1) in vitro negatively influences Candida albicans virulence in the rabbit model of infective endocarditis (IE). This study evaluated the relationship between in vitro tPMP-1 susceptibility (tPMP-1s) or resistance (tPMP-1r) and efficacy of fluconazole (FLU) therapy of IE due to C. albicans. Candida IE was established in rabbits with either tPMP-1s or tPMP-1r strains. Treatment groups received FLU (100 mg/kg/day) intraperitoneally for 7 or 14 days; control animals received no therapy. At these time points, cardiac vegetations, kidneys, and spleens were quantitatively cultured to assess fungal burden. At both 7 and 14 days and in all target tissues, the extent of candidal clearance by FLU was greater in animals infected with the tPMP-1s strain than in those infected with the tPMP-1r strain. These differences were statistically significant in the spleen and kidney. Corroborating these in vivo data, FLU (a candidastatic agent), in combination with tPMP-1, exerted an enhanced fungicidal effect in vitro against tPMP-1s and tPMP-1r C. albicans, with the extent of this effect greatest against the tPMP-1s strain. Collectively, these results support the concept that tPMP-1 susceptibility contributes to the net efficacy of FLU against C. albicans IE in vivo, particularly in tissues in which platelets and tPMP-1 likely play significant roles in host defense.


Asunto(s)
Antifúngicos/uso terapéutico , Proteínas Sanguíneas/uso terapéutico , Candidiasis/tratamiento farmacológico , Endocarditis/tratamiento farmacológico , Fluconazol/uso terapéutico , Animales , Proteínas Sanguíneas/farmacología , Candida albicans/efectos de los fármacos , Candidiasis/microbiología , Recuento de Colonia Microbiana , Evaluación Preclínica de Medicamentos , Sinergismo Farmacológico , Endocarditis/microbiología , Corazón/microbiología , Riñón/microbiología , Pruebas de Sensibilidad Microbiana , Especificidad de Órganos , Conejos , Especificidad de la Especie , Bazo/microbiología
9.
Antimicrob Agents Chemother ; 45(2): 485-94, 2001 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-11158745

RESUMEN

In vitro time-kill studies and a rabbit model of endocarditis and pyelonephritis were used to define the impact that the order of exposure of Candida albicans to fluconazole (FLC) and amphotericin B (AMB), as sequential and combination therapies, had on the susceptibility of C. albicans to AMB and on the outcome. The contribution of FLC-induced resistance to AMB for C. albicans also was assessed. In vitro, AMB monotherapy rapidly killed each of four C. albicans strains; FLC alone was fungistatic. Preincubation of these fungi with FLC for 18 h prior to exposure to AMB decreased their susceptibilities to AMB for 8 to >40 h. Induced resistance to AMB was transient, but the duration of resistance increased with the length of FLC preincubation. Yeast sequentially incubated with FLC followed by AMB plus FLC (FLC-->AMB+FLC) showed fungistatic growth kinetics similar to that of fungi that were exposed to FLC alone. This antagonistic effect persisted for at least 24 h. Simultaneous exposure of C. albicans to AMB and FLC [AMB+FLC(simult)] demonstrated activity similar to that with AMB alone for AMB concentrations of > or =1 microg/ml; antagonism was seen using an AMB concentration of 0.5 microg/ml. The in vitro findings accurately predicted outcomes in our rabbit infection model. In vivo, AMB monotherapy and treatment with AMB for 24 h followed by AMB plus FLC (AMB-->AMB+FLC) rapidly sterilized kidneys and cardiac vegetations. AMB+FLC(simult) and FLC-->AMB treatments were slower in clearing fungi from infected tissues. FLC monotherapy and FLC-->AMB+FLC were both fungistatic and were the least active regimens. No adverse interaction was observed between AMB and FLC for the AMB-->FLC regimen. However, FLC-->AMB treatment was slower than AMB alone in clearing fungi from tissues. Thus, our in vitro and in vivo studies both demonstrate that preexposure of C. albicans to FLC reduces fungal susceptibility to AMB. The length of FLC preexposure and whether AMB is subsequently used alone or in combination with FLC determine the duration of induced resistance to AMB.


Asunto(s)
Anfotericina B/uso terapéutico , Antifúngicos/uso terapéutico , Candida albicans/efectos de los fármacos , Endocarditis/microbiología , Fluconazol/uso terapéutico , Pielonefritis/microbiología , Anfotericina B/farmacocinética , Anfotericina B/farmacología , Animales , Antifúngicos/farmacocinética , Antifúngicos/farmacología , Área Bajo la Curva , Fluconazol/farmacocinética , Fluconazol/farmacología , Corazón/microbiología , Riñón/microbiología , Pruebas de Función Renal , Masculino , Pruebas de Sensibilidad Microbiana , Conejos , Factores de Tiempo
10.
J Immunol ; 162(2): 948-56, 1999 Jan 15.
Artículo en Inglés | MEDLINE | ID: mdl-9916719

RESUMEN

A spectrum of disease severity has been observed in patients with Lyme disease, with approximately 60% of untreated individuals developing arthritis. The murine model of Lyme disease has provided strong evidence that the genetic composition of the host influences the severity of arthritis following infection with Borrelia burgdorferi: infected C3H mice develop severe arthritis while infected C57BL/6N mice develop mild arthritis. Regions of the mouse genome controlling arthritis severity and humoral responses during B. burgdorferi infection were identified in the F2 intercross generation of C3H/HeNCr and C57BL/6NCr mice. Rear ankle swelling measurements identified quantitative trait loci (QTL) on chromosomes 4 and 5, while histopathological scoring identified QTL on a unique region of chromosome 5 and on chromosome 11. The identification of QTL unique for ankle swelling or histopathological severity suggests that processes under distinct genetic control are responsible for these two manifestations of Lyme arthritis. Additional QTL that control the levels of circulating Igs induced by B. burgdorferi infection were identified on chromosomes 6, 9, 11, 12, and 17. Interestingly, the magnitude of the humoral response was not correlated with the severity of arthritis in infected F2 mice. This work defines several genetic loci that regulate either the severity of arthritis or the magnitude of humoral responses to B. burgdorferi infection in mice, with implications toward understanding the host-pathogen interactions involved in disease development.


Asunto(s)
Anticuerpos Antibacterianos/biosíntesis , Artritis/genética , Artritis/inmunología , Enfermedad de Lyme/genética , Enfermedad de Lyme/inmunología , Carácter Cuantitativo Heredable , Animales , Artritis/microbiología , Artritis/patología , Grupo Borrelia Burgdorferi/inmunología , Mapeo Cromosómico , Cruzamientos Genéticos , ADN Bacteriano/metabolismo , Femenino , Ligamiento Genético , Marcadores Genéticos , Corazón/microbiología , Enfermedad de Lyme/microbiología , Enfermedad de Lyme/patología , Masculino , Ratones , Ratones Endogámicos C3H , Ratones Endogámicos C57BL , Índice de Severidad de la Enfermedad
11.
Cardiovasc Drugs Ther ; 10(3): 351-60, 1996 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-8877079

RESUMEN

It is suggested that Borrelia burgdorferi infection could be associated with dilated cardiomyopathy (IDC). Stanek et al. were able to cultivate Borrelia burgdorferi from myocardial biopsy tissue of a patient with longstanding dilated cardiomyopathy. Here we present a study in which we examined the effect of standard antibiotic treatment on the left ventricular ejection fraction (LVEF) in patients with dilated cardiomyopathy associated with Borrelia burgdorferi infection. In this study we assessed the serum (IgG, IgM Elisa) and history of 46 IDC patients with specific regard to Borrelia burgdorferi infection (mean LVEF 30.4 +/- 1.3%, measured by cardiac catheterization and echocardiography with the length-area-volume method). All 46 patients received standard treatment for dilated cardiomyopathy: ACE inhibitors, digitalis, and diuretics. Eleven (24%) patients showed positive serology and a history of Borrelia burgdorferi infection; nine of these also had a typical history of tick bite and erythema chronicum migrans (ECM) and/or other organ involvement, and two had no recollection of tick bite or ECM but showed other Borrelia burgdorferi-associated disorders (neuropathy, oligoarthritis). These 11 patients with Borrelia burgdorferi infection received standard antibiotic treatment with intravenous ceftriaxone 2 g bid for 14 days. Six (55%) recovered completely and showed a normal LVEF after 6 months, three (27%) improved their LVEF, and two (18%) did not improve at all. This amounts to nine (82%) patients with recovery/improvement in the Borrelia burgdorferi group. The 35 patients who did not show positive serology or a history of Borrelia burgdorferi infection did not receive antibiotic treatment. In this group without Borrelia burgdorferi infection 12 (26%), showed recovery/improvement following the standard treatment of dilated cardiomyopathy (see earlier). Our results indicate that Borrelia burgdorferi infection could play a decisive role in the development of dilated cardiomyopathy, especially in a geographical region such as Graz, where Borrelia burgdorferi is endemic. While we are aware of the small number of Borrelia burgdorferi patients in this study, we nevertheless conclude that in a remarkable number of patients with signs of Borrelia burgdorferi infection, dilated cardiomyopathy could be reversed and LVEF improved.


Asunto(s)
Infecciones por Borrelia/tratamiento farmacológico , Grupo Borrelia Burgdorferi/efectos de los fármacos , Cardiomiopatía Dilatada/tratamiento farmacológico , Ceftriaxona/uso terapéutico , Cefalosporinas/uso terapéutico , Volumen Sistólico/efectos de los fármacos , Adolescente , Adulto , Anciano , Inhibidores de la Enzima Convertidora de Angiotensina/administración & dosificación , Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Infecciones por Borrelia/diagnóstico , Infecciones por Borrelia/fisiopatología , Cardiomiopatía Dilatada/diagnóstico , Cardiomiopatía Dilatada/epidemiología , Cardiomiopatía Dilatada/microbiología , Ceftriaxona/administración & dosificación , Ceftriaxona/efectos adversos , Ceftriaxona/farmacología , Cefalosporinas/administración & dosificación , Cefalosporinas/farmacología , Distribución de Chi-Cuadrado , Medios de Cultivo , Digitalis , Diuréticos/administración & dosificación , Diuréticos/uso terapéutico , Electrocardiografía , Femenino , Corazón/microbiología , Humanos , Inmunoglobulina G/sangre , Inyecciones Intravenosas , Masculino , Persona de Mediana Edad , Plantas Medicinales , Plantas Tóxicas
12.
J Infect Dis ; 170(2): 351-7, 1994 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-8035022

RESUMEN

Coxsackievirus B3 (CVB3/20)-induced myocarditic lesions occurred more quickly and were more severe and virus titers in heart and liver were higher in selenium (Se)-deficient than Se-adequate mice. NK cell activity and serum neutralizing antibody titers were similar in both Se-adequate and -deficient CVB3/20-infected mice; however, lymphocyte proliferation to both mitogen and antigen was decreased in Se-deficient mice. CVB3/20 isolated from Se-deficient donor mice and inoculated into Se-adequate recipient mice induced severe myocarditis. In contrast, CVB3/20 isolated from Se-adequate donor mice and inoculated into Se-adequate recipient mice induced only moderate myocarditis, similar to that caused by the original virus stock. Thus, the general population of CVB3/20 virions, as a consequence of replicating in an Se-deficient host, underwent a phenotypic change to increased virulence. These results have important implications for the emergence of virulent viruses.


Asunto(s)
Infecciones por Coxsackievirus/microbiología , Enterovirus Humano B/patogenicidad , Miocarditis/microbiología , Selenio/deficiencia , Animales , Infecciones por Coxsackievirus/patología , Glutatión Peroxidasa/sangre , Corazón/microbiología , Células Asesinas Naturales/inmunología , Hígado/microbiología , Activación de Linfocitos , Masculino , Ratones , Miocarditis/patología , Miocardio/patología , Pase Seriado , Virulencia
13.
J Antimicrob Chemother ; 32 Suppl B: 95-101, 1993 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-8150772

RESUMEN

The efficacy of cefepime, a new broad-spectrum cephalosporin, was compared with those of cefpirome, ceftazidime, vancomycin, imipenem-cilastatin and penicillin G in a rat model of endocarditis caused by a methicillin-susceptible strain of Staphylococcus aureus. Rats were infected intravenously with approximately 10(5) cfu of a penicillin-resistant strain of S. aureus 24 h after placement of a catheter into the left ventricle of the heart via the carotid artery. Efficacy was evaluated by comparing bacterial counts in the cardiac vegetations of treated rats with those of untreated controls. Rats treated with cefepime, cefpirome, ceftazidime, imipenem-cilastatin and vancomycin showed a reduction in the number of bacteria recovered from cardiac vegetations compared with infected control animals; penicillin G was ineffective in this respect. Serum concentrations of the study antimicrobials were determined at selected times following the administration of a single subcutaneous dose. The pharmacokinetic parameters of the cephalosporins were similar in these animals. This study shows that cefepime may be of value in the treatment of staphylococcal endocarditis.


Asunto(s)
Cefalosporinas/uso terapéutico , Endocarditis Bacteriana/tratamiento farmacológico , Infecciones Estafilocócicas/tratamiento farmacológico , Animales , Antibacterianos/uso terapéutico , Cefepima , Cefalosporinas/farmacocinética , Endocarditis Bacteriana/microbiología , Semivida , Corazón/microbiología , Masculino , Pruebas de Sensibilidad Microbiana , Ratas , Ratas Sprague-Dawley , Infecciones Estafilocócicas/microbiología , Staphylococcus aureus/efectos de los fármacos
14.
Antimicrob Agents Chemother ; 37(9): 2030-2, 1993 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-8239628

RESUMEN

Amphotericin B and fluconazole were compared for the treatment of experimental Candida endocarditis caused by Candida tropicalis and C. parapsilosis. Rabbits received no therapy, amphotericin B (1 mg/kg of body weight per day intravenously), or fluconazole (100 mg/kg/day intraperitoneally) for either 11 or 21 days. Against both species, amphotericin B and fluconazole were equally effective overall; however, amphotericin B was more rapidly fungicidal than fluconazole in vivo against C. tropicalis.


Asunto(s)
Anfotericina B/uso terapéutico , Candidiasis/tratamiento farmacológico , Endocarditis/tratamiento farmacológico , Fluconazol/uso terapéutico , Anfotericina B/administración & dosificación , Anfotericina B/farmacología , Animales , Candida/efectos de los fármacos , Candidiasis/microbiología , Endocarditis/microbiología , Femenino , Fluconazol/administración & dosificación , Fluconazol/farmacología , Corazón/microbiología , Inyecciones Intravenosas , Pruebas de Sensibilidad Microbiana , Conejos
15.
Antimicrob Agents Chemother ; 37(6): 1329-33, 1993 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-8328782

RESUMEN

Clarithromycin provided effective therapy against arthritis induced by Borrelia burgdorferi infection in the hamster. In vitro, clarithromycin was at least 1 log more potent than tetracycline against two isolates of B. burgdorferi from human sources, as measured by MICs and 50% inhibitory concentrations. Clarithromycin was effective in preventing the onset of B. burgdorferi-induced arthritis, as determined by several parameters of paw swelling. When administered after the onset of arthritis, clarithromycin therapy reduced the degree of swelling and decreased recovery time. These results suggest that clarithromycin has potential as an effective therapy for Lyme disease.


Asunto(s)
Grupo Borrelia Burgdorferi/efectos de los fármacos , Claritromicina/farmacología , Modelos Animales de Enfermedad , Enfermedad de Lyme/tratamiento farmacológico , Animales , Anticuerpos Antibacterianos/análisis , Grupo Borrelia Burgdorferi/inmunología , Claritromicina/sangre , Claritromicina/farmacocinética , Cricetinae , Corazón/microbiología , Humanos , Riñón/microbiología , Enfermedad de Lyme/sangre , Enfermedad de Lyme/inmunología , Mesocricetus , Pruebas de Sensibilidad Microbiana , Bazo/microbiología , Vejiga Urinaria/microbiología
16.
Zentralbl Bakteriol ; 271(3): 293-303, 1989 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-2803457

RESUMEN

The pathogenicity of Legionella pneumophila, serogroup 1, strain Nottingham N7, was assessed in terms of LD50 data and the ability of the organism to induce pathological lesions in the fertile hen's egg. Histopathological examination of embryo organs after inoculation with 1, 10, 100 and 1000 times the yolk sac LD50 revealed a disseminated infection. Systemic spread of the organism resulted in widespread necrosis and evidence of consolidation together with generation of copious amounts of oedema fluid. These were particularly severe in the liver, heart, spleen and kidney. The infection elicited a massive inflammatory response typified by infiltration with polymorphonuclear leucocytes and lymphocytes. Selected antimicrobial chemotherapeutic agents were investigated in protection studies for their capacity to ameliorate or control disease processes in this test system. Of those examined ciprofloxacin was most effective in reducing the incidence of lesions in these tissues and for prolonging embryo viability. Rifampicin, and to a lesser degree, erythromycin and doxycycline, also showed antimicrobial activity in these in vivo trials. These results indicate that the fertile hen's egg may be a useful alternative to other animal systems for the in vivo testing of clinically putative antimicrobial agents in the treatment of Legionnaires' disease.


Asunto(s)
Ciprofloxacina/uso terapéutico , Enfermedad de los Legionarios/etiología , Animales , Embrión de Pollo , Ciprofloxacina/farmacología , Recuento de Colonia Microbiana , Doxiciclina/farmacología , Eritromicina/farmacología , Corazón/microbiología , Riñón/microbiología , Riñón/patología , Legionella/efectos de los fármacos , Legionella/crecimiento & desarrollo , Enfermedad de los Legionarios/tratamiento farmacológico , Enfermedad de los Legionarios/patología , Hígado/microbiología , Hígado/patología , Miocardio/patología , Rifampin/farmacología , Bazo/microbiología , Bazo/patología
17.
Acta Pathol Microbiol Immunol Scand B ; 90(1): 25-35, 1982 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-6805249

RESUMEN

A previously described model of experimental Streptococcus faecalis endocarditis in rabbits without an indwelling catheter during the infectious processes was used to study the effect of long-term treatment with antibiotics. Groups of animals infected with six different strains were treated for four weeks and the following parameters were determined: survival rate, bacterial concentration in blood and vegetations, signs at autopsy indicating congestive heart failure. Before the therapeutic experiments, the tolerance of the rabbit to long-term exposure of the drugs penicillin and streptomycin was considered in a group of non-infected animals. Two out of 20 rabbits died with enteritis during the penicillin exposure, and a general weight reduction was observed. Streptomycin was apparently completely harmless. There was no therapeutic effect of streptomycin on S. faecalis endocarditis due to strains all designated resistant to streptomycin by MIC, except in rabbits infected with a strain, which showed partial susceptibility to the drug by IC50. Regardless of the therapeutic effect, evidence was obtained for rapid development of increased resistance of the infecting strains towards streptomycin. After long-term treatment with penicillin in either low or high dose some of the animals survived and the valves were sterilized in 37% of the animals after low-dose and in 39% after high-dose. It was observed that congestive heart failure occurred with the greatest frequency and intensity after infection with proteolytic strains.


Asunto(s)
Endocarditis Bacteriana/tratamiento farmacológico , Penicilinas/uso terapéutico , Infecciones Estreptocócicas/tratamiento farmacológico , Estreptomicina/uso terapéutico , Animales , Enterococcus faecalis/efectos de los fármacos , Corazón/microbiología , Pruebas de Sensibilidad Microbiana , Tamaño de los Órganos , Penicilinas/toxicidad , Conejos , Estreptomicina/toxicidad
18.
Acta Pathol Microbiol Immunol Scand B ; 90(1): 37-47, 1982 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-6805250

RESUMEN

The synergistic action of penicillin and streptomycin was investigated on animals with experimental endocarditis, using the previously described model and four different strains of Streptococcus faecalis. Two strains represented a moderate and two strains a high level of resistance to streptomycin. The purpose was to determine the effect of the combined penicillin and streptomycin treatment, since previous in vitro investigations showed that strains highly resistant to streptomycin were also resistant to combination of the drugs. Antibiotic treatment of the animals was carried out for 28 days, followed by a period of four weeks observation. The treatment resulted in a demonstrable effect against infection caused by the least streptomycin-resistant strain, but was completely ineffective in rabbits infected with the strain homogeneously resistant to 8000 micrograms/ml streptomycin. The synergistic effect of penicillin and streptomycin towards strains within a range of streptomycin resistance of 2000-8000 micrograms/ml could be predicted by the IC50 test, but not by MIC or the in vitro killing curve test for synergism. Besides the therapeutic results, this report also considers the following features: pathoanatomic and physiologic processes related to the number of viable bacteria in the endocardial vegetations; the influence of the proteolytic capacity of infecting strains; the development of congestive heart failure.


Asunto(s)
Endocarditis Bacteriana/tratamiento farmacológico , Penicilinas/administración & dosificación , Infecciones Estreptocócicas/tratamiento farmacológico , Estreptomicina/administración & dosificación , Animales , Sinergismo Farmacológico , Quimioterapia Combinada , Enterococcus faecalis/efectos de los fármacos , Corazón/microbiología , Insuficiencia Cardíaca/etiología , Riñón/microbiología , Pruebas de Sensibilidad Microbiana , Miocardio/patología , Tamaño de los Órganos , Conejos , Sepsis/microbiología , Bazo/microbiología
19.
Aviat Space Environ Med ; 48(9): 863-6, 1977 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-907597

RESUMEN

A study was undertaken to weigh the effects of air pollution and oxygen at high pressure on the susceptibility of mice to Coxsackievirus B1 infection. Animals exposed to air pollutants or oxygen at high pressure were found to contain higher amounts of recoverable virus than control animals. Animals exposed to both air pollutants and oxygen at high pressure were found to contain the greatest levels of recoverable virus. This same group of animals was also found to have hearts which were smaller than any other group. Animals maintained in an ambient atmosphere had higher levels of recoverable virus and smaller hearts than animals exposed to terpene vapors and hyperbaric oxygen. The results of this study suggest that terpene vapors may nullify the activity of oxygen at high pressure.


Asunto(s)
Contaminantes Atmosféricos/toxicidad , Enterovirus/efectos de los fármacos , Oxigenoterapia Hiperbárica , Terpenos/toxicidad , Replicación Viral/efectos de los fármacos , Animales , Enterovirus/aislamiento & purificación , Femenino , Corazón/anatomía & histología , Corazón/microbiología , Ratones , Ratones Endogámicos , Tamaño de los Órganos , Embarazo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA